Skip to content
1887

Journal of General Virology header logo Journal of General Virology

Volume 82, Issue 12

Circulating tumour necrosis factor-α and interferon-γ are detectable during acute and convalescent parvovirus B19 infection and are associated with prolonged and chronic fatigue No Access

Abstract

To investigate whether cytokine responses may have a bearing on the symptoms and outcome of parvovirus B19 infection, circulating cytokines were measured during acute infection (=51), follow-up of acute infection (=39) and in normal healthy controls (=50). At acute B19 virus infection (serum anti-B19 IgM-positive), patients ranged in age from 4 to 54 years, with a mean age of 28·2 years. The male:female ratio was 1:4·1 and symptoms were rash (=15), arthralgia (=31), fatigue (=8), lymphadenopathy (=4), foetal hydrops (=3), transient aplastic crisis (=2), neutropenia (=2), myelodysplasia (=1), thrombocytopenia (=1) and pancytopenia (=1). Of these patients, 39 were contacted after a follow-up period of 2–37 months (mean of 22·5 months). In comparison with normal controls, detectable IL-6 was associated with acute B19 virus infection (26%; =0·0003), but not with follow-up (6%; =0·16). Detection of interferon (IFN)-γ was associated with acute B19 virus infection (67%; <0·0001) and follow-up (67%; <0·0001). Detection of tumour necrosis factor (TNF)-α was associated with acute B19 virus infection (49%; <0·0001) and follow-up (56%; <0·0001). IL-1β was detected in acute infection (20%), but not at follow-up. At acute B19 virus infection, detection of serum/plasma IL-6 was associated with rheumatoid factor (=0·038) and IFN-γ (⩾7 pg/ml) was associated with fatigue in those patients of ⩾15 years of age (=0·022). At follow-up, fatigue was associated with IFN-γ (⩾7 pg/ml) and/or TNF-α (⩾40 pg/ml) (=0·0275). Prolonged upregulation of serum IFN-γ and TNF-α appears to represent a consistent host response to symptomatic B19 virus infection.

  • Received:
  • Accepted:
  • Published Online:
© Microbiology Society
Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-82-12-3011
2001-12-01
2025-07-12
Loading full text...

Full text loading...

References

  1. Anderson M. J., Higgins P. G., Davis L. R., Willman J. S., Jones S. E., Kidd I. M., Pattison J. R., Tyrrell D. A. J. 1985; Experimental parvoviral infection in humans. Journal of Infectious Diseases 152:257–265
     [Google Scholar]
  2. Bauder B., Suchy A., Gabler C., Weissenbock H. 2000; Apoptosis in feline panleukopenia and canine parvovirus enteritis. Journal of Veterinary Medicine Series B 47:775–784
     [Google Scholar]
  3. Choy E. H. S., Panayi G. S. 2001; Cytokine pathways and joint inflammation in rheumatoid arthritis. New England Journal of Medicine 344:907–916
     [Google Scholar]
  4. Chung Y. H., Jun H. S., Kang Y., Hirasawa K., Lee B. R., Van Rooijen H., Yoon J. W. 1997; Role of macrophages and macrophage-derived cytokines in the pathogenesis of Kilham rat virus-induced autoimmune diabetes: diabetes-resistant biobreeding rats. Journal of Immunology 159:466–471
     [Google Scholar]
  5. Coker A. L., Russell R. B., Bond S. M., Pirisi L., Liu Y., Mane M., Kokorina N., Gerasimova T., Hermonat P. L. 2001; Adeno-associated virus is associated with a lower risk of high-grade cervical neoplasia. Experimental and Molecular Pathology 70:83–89
     [Google Scholar]
  6. Corcoran A., Doyle S., Waldron D., Nicholson A., Mahon B. P. 2000; Impaired gamma interferon responses against parvovirus B19 by recently infected children. Journal of Virology 74:9903–9910
     [Google Scholar]
  7. Cossart Y. E., Field A. M., Cant B., Widdow D. 1976; Parvovirus-like particles in human sera. Lancet 1:72–73
     [Google Scholar]
  8. Durigon E. L., Erdman D. D., Gary G. W., Pallansch M. A., Torok T. J., Anderson L. J. 1993; Multiple primer pairs for polymerase chain reaction (PCR) amplification of human parvovirus B19 DNA. Journal of Virological Methods 44:155–165
     [Google Scholar]
  9. Feldmann M., Maini R. N. 2001; Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?. Annual Review of Immunology 19:163–196
     [Google Scholar]
  10. Franssila R., Soderlund M., Brown S. B., Spaan W. J. M., Seppala I., Hedman K. 1996; IgG response to human parvovirus B19 infection. Clinical & Diagnostic Virology 6:41–49
     [Google Scholar]
  11. Fukuda K., Straus S. E., Hickie I., Sharpe M. C., Dobbins J. G., Komaroff A. L. The International Chronic Fatigue Syndrome Study Group 1994; The chronic fatigue syndrome: a comprehensive approach to its definition and study. Annals of Internal Medicine 121:953–959
     [Google Scholar]
  12. Georg-Fries B., Biederlack S., Wolf J., zur Hausen H. 1984; Analysis of proteins, helper dependence, and seroepidemiology of a new human parvovirus. Virology 134:64–71
     [Google Scholar]
  13. Goodbourn S., Didcock L., Randall R. E. 2000; Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. Journal of General Virology 81:2341–2364
     [Google Scholar]
  14. Holt I., Cooper R. G., Hopkins S. J. 1991; Relationships between local inflammation, interleukin-6 concentration and the acute phase protein response in arthritis patients. European Journal of Clinical Investigation 21:479–484
     [Google Scholar]
  15. Hunter C. A., Reiner S. L. 2000; Cytokines and T cells in host defense. Current Opinion in Immunology 12:413–418
     [Google Scholar]
  16. Ikeda Y., Shinozuka J., Miyazawa T., Kurosawa K., Izumiya Y., Nishimura Y., Nakamura K., Cai J., Fujita K., Doi K., Mikami T. 1998; Apoptosis in feline panleukopenia virus-infected lymphocytes. Journal of Virology 72:6932–6936
     [Google Scholar]
  17. Ishii K. K., Takahashi Y., Kaku M., Sasaki T. 1999; Role of human parvovirus B19 in the pathogenesis of rheumatoid arthritis. Japanese Journal of Infectious Diseases 52:201–207
     [Google Scholar]
  18. Jordan J. A., Huff D., DeLoia J. A. 2001; Placental cellular immune response in women infected with human parvovirus B19 during pregnancy. Clinical and Diagnostic Laboratory Immunology 8:288–292
     [Google Scholar]
  19. Kerr J. R. 2000; Pathogenesis of human parvovirus B19 in rheumatic disease. Annals of the Rheumatic Diseases 59:672–683
     [Google Scholar]
  20. Kerr J. R., O’Neill H. J., Deleys R. J., Wright C., Coyle P. V. 1995; Design and production of a target-specific monoclonal antibody to parvovirus B19 capsid proteins. Journal of Immunological Methods 180:101–106
     [Google Scholar]
  21. Kurtzman G. J., Frickhofen N. K., Kimball J., Jenkins D. W., Nienhuis A. W., Young N. S. 1989; Pure red-cell aplasia of 10 years’ duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. New England Journal of Medicine 321:519–523
     [Google Scholar]
  22. Lejeune F. J., Ruegg C., Lienard D. 1998; Clinical applications of TNF-α in cancer. Current Opinion in Immunology 10:573–580
     [Google Scholar]
  23. Mani S., Poo W. J. 1996; Single institution experience with recombinant gamma-interferon in the treatment of patients with metastatic renal cell carcinoma. American Journal of Clinical Oncology 19:149–153
     [Google Scholar]
  24. Mayor H. D., Drake S., Stahmann J., Mumford D. M. 1976; Antibodies to adeno-associated satellite virus and herpes simplex virus in sera from cancer patients and normal adults. American Journal of Obstetrics and Gynecology 126:100–104
     [Google Scholar]
  25. Moffatt S., Tanaka N., Tada K., Nose M., Nakamura M., Muraoka O., Hirano T., Sugamura K. 1996; A cytotoxic nonstructural protein, NS1, of human parvovirus B19 induces activation of interleukin-6 gene expression. Journal of Virology 70:8485–8491
     [Google Scholar]
  26. Moffatt S., Yaegashi N., Tada K., Tanaka N., Sugamura K. 1998; Human parvovirus B19 nonstructural (NS1) protein induces apoptosis in erythroid lineage cells. Journal of Virology 72:3018–3028
     [Google Scholar]
  27. Moss R. B., Mercandetti A., Vojdani A. 1999; TNF-α and chronic fatigue syndrome. Journal of Clinical Immunology 19:314–316
     [Google Scholar]
  28. Nigro G., Bastianon V., Colloridi V., Ventriglia F., Gallo P., D’Amati G., Koch W. C., Adler S. P. 2000; Human parvovirus B19 infection in infancy associated with acute and chronic lymphocytic myocarditis and high cytokine levels: report of 3 cases and review. Clinical Infectious Diseases 31:65–69
     [Google Scholar]
  29. Ohshima T., Iwana M., Ueno Y., Sugiyama F., Nakajima T., Fukamizu A., Yagami K.-i. 1998; Induction of apoptosis in vitro and in vivo by H-1 parvovirus infection. Journal of General Virology 79:3067–3071
     [Google Scholar]
  30. Otto C. M., Drobatz K. J., Soter C. 1997; Endotoxemia and tumor necrosis factor activity in dogs with naturally occurring parvoviral enteritis. Journal of Veterinary Internal Medicine 11:65–70
     [Google Scholar]
  31. Patarca R., Klimas N. G., Lugtendorf S., Antoni M., Fletcher M. A. 1994; Dysregulated expression of tumor necrosis factor in chronic fatigue syndrome: interrelations with cellular sources and patterns of soluble immune mediator expression. Clinical Infectious Diseases 18 (Suppl. 1):S147–S153
     [Google Scholar]
  32. Pattison J. R., Jones S. E., Hodgson J., Davis L. R., White J. M., Stroud C. E., Murtaza L. 1981; Parvovirus infections and hypoplastic crisis in sickle-cell anaemia. Lancet 1:664–665
     [Google Scholar]
  33. Penttila I. A., Harris R. J., Storm P., Haynes D., Worswick D. A., Marmion B. P. 1998; Cytokine dysregulation in the post-Q-fever fatigue syndrome. Quarterly Journal of Medicine 91:549–560
     [Google Scholar]
  34. Rasmussen A. K., Nielsen H., Andersen V., Barington T., Bendtzen K., Hansen M. B., Neilsen L., Pedersen B. K., Wiik A. 1994; Chronic fatigue syndrome – a controlled cross-sectional study. Journal of Rheumatology 21:1527–1531
     [Google Scholar]
  35. Rayet B., Lopez-Guerrero J. A., Rommelaere J., Dinsart C. 1998; Induction of programmed cell death by parvovirus H-1 in U937 cells: connection with the tumor necrosis factor alpha signalling pathway. Journal of Virology 72:8893–8903
     [Google Scholar]
  36. Rommelaere J., Cornelis J. J. 1991; Antineoplastic activity of parvoviruses. Journal of Virological Methods 33:233–251
     [Google Scholar]
  37. Schlehofer J. R., Rentrop M., Mannel D. N. 1992; Parvoviruses are inefficient in inducing interferon-β, tumor necrosis factor-α, or interleukin-6 in mammalian cells. Medical Microbiology and Immunology 181:153–164
     [Google Scholar]
  38. Schwarz T. F., Roggendorf B., Hottentrager B., Modrow S., Deinhardt F., Middeldorp J. 1990; Immunoglobulins in the prophylaxis of parvovirus B19 infection. Journal of Infectious Diseases 162:1214
     [Google Scholar]
  39. Segovia J. C., Gallego J. M., Bueren J. A., Almendral J. M. 1999; Severe leukopenia and dysregulated erythropoiesis in SCID mice persistently infected with the parvovirus minute virus of mice. Journal of Virology 73:1774–1784
     [Google Scholar]
  40. Shade R. O., Blundell M. C., Cotmore S. F., Tattersall P., Astell C. R. 1986; Nucleotide sequence and genome organization of human parvovirus B19 isolated from the serum of a child during aplastic crisis. Journal of Virology 58:921–936
     [Google Scholar]
  41. Shingu M., Nagai Y., Isayama T., Naono T., Nobunaga M., Nagai Y. 1993; The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase production by human chondrocytes and TIMP production by synovial cells and endothelial cells. Clinical and Experimental Immunology 94:145–149
     [Google Scholar]
  42. Sol N., Le Junter H., Vassias I., Freyssinier J. M., Thomas A., Prigent A. F., Rudkin B. B., Fichelson S., Morinet F. 1999; Possible interactions between the NS-1 protein and tumor necrosis factor alpha pathways in erythroid cell apoptosis induced by parvovirus B19. Journal of Virology 73:8762–8770
     [Google Scholar]
  43. Sprecher-Goldberger S., Thiry L., Lefèbvre N., Dekegel D., de Halleux F. 1971; Complement-fixation antibodies to adeno-associated viruses, cytomegaloviruses and herpes simplex viruses in patients with tumours and in control individuals. American Journal of Epidemiology 94:351–358
     [Google Scholar]
  44. Takahashi Y., Murai C., Shibata S., Munakata Y., Ishii T., Ishii K., Saitoh T., Sawai T., Sugamura K., Sasaki T. 1998; Human parvovirus B19 as a causative agent for rheumatoid arthritis. Proceedings of the National Academy of Sciences, USA 95:8227–8232
     [Google Scholar]
  45. von Poblotzki A., Gerdes C., Reischl U., Wolf H., Modrow S. 1996; Lymphoproliferative responses after infection with human parvovirus B19. Journal of Virology 70:7327–7330
     [Google Scholar]
  46. Wagner A. D., Goronzy J. J., Matteson E. L., Weyand C. M. 1995; Systemic monocyte and T-cell activation in a patient with human parvovirus B19 infection. Mayo Clinic Proceedings 70:261–265
     [Google Scholar]
  47. Watanabe M., Shimamoto Y., Yamaguchi M., Inada S., Miyazaki S., Sato H. 1994; Viral-associated haemophagocytosis and elevated serum TNF-α with parvovirus B19-related pancytopenia in patients with hereditary spherocytosis. Clinical and Laboratory Hematology 16:179–182
     [Google Scholar]
  48. Zhou C., Trempe J. P. 1999; Induction of apoptosis by cadmium and the adeno-associated virus Rep proteins. Virology 261:280–287
     [Google Scholar]
/content/journal/jgv/10.1099/0022-1317-82-12-3011
Loading
Circulating tumour necrosis factor-α and interferon-γ are detectable during acute and convalescent parvovirus B19 infection and are associated with prolonged and chronic fatigue
J. Gen. Virol. 82, 3011 (2001); https://doi.org/10.1099/0022-1317-82-12-3011
/content/journal/jgv/10.1099/0022-1317-82-12-3011
/content/journal/jgv/10.1099/0022-1317-82-12-3011
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error